Michael Ehlers
Neuroscience Chief Scientific Officer
Pfizer
From this contributor
A cautionary tale for autism drug development
Poorly designed animal drug studies for motor disorders have led to spurious conclusions for the clinical trials that follow. This may be even more true for autism research, says Michael Ehlers.
SHANK mutations converge at neuronal junctions in autism
SHANK3, one of the strongest candidate genes for autism, has the potential to be a molecular entry point into understanding the synaptic, developmental and circuit origins of the disorder.
SHANK mutations converge at neuronal junctions in autism
Drug zone
Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.
Explore more from The Transmitter
Finding neuroheterogeneity’s sweet spot
Once thought to be detrimental to memory processing, neuronal diversity—at the right ‘Goldilocks’ dose—is a new boon to theoretical neuroscience.
Finding neuroheterogeneity’s sweet spot
Once thought to be detrimental to memory processing, neuronal diversity—at the right ‘Goldilocks’ dose—is a new boon to theoretical neuroscience.
COVID-19 and influenza effects in pregnancy; and more
Here is a roundup of autism-related news and research spotted around the web for the week of 19 October.
COVID-19 and influenza effects in pregnancy; and more
Here is a roundup of autism-related news and research spotted around the web for the week of 19 October.
What to do when traditional mechanistic approaches no longer work
Many complex behaviors have stubbornly resisted mechanistic explanations. Deciphering them will require new approaches—and perhaps a new concept of “understanding.”
What to do when traditional mechanistic approaches no longer work
Many complex behaviors have stubbornly resisted mechanistic explanations. Deciphering them will require new approaches—and perhaps a new concept of “understanding.”